Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 0.80 |
| ▸ | HTR3A | P46098 | 6/20 | 0.64 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.64 |
| ▸ | HTR3B | O95264 | 5/20 | 0.64 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.64 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373736 | 0.89 | CHRNA7 (1.00) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6881216 | 0.89 | CHRNA7 (0.81) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL834016 | 0.89 | CHRNA7 (1.00) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6873009 | 0.88 | CHRNA7 (0.80) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6881399 | 0.88 | CHRNA7 (0.80) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6882647 | 0.88 | CHRNA7 (0.80) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL372855 | 0.88 | CHRNA7 (0.85) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL13496959 | 0.85 | CHRNA7 (0.76) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6883592 | 0.84 | CHRNA7 (0.74) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6883132 | 0.84 | CHRNA7 (0.74) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052389-A1 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic-acetylcholine receptor is implicated | PHARMACIA & UPJOHN COMPANY | 2002-05-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052389-A1 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic-acetylcholine receptor is implicated | CHRNA7, CHRNA1, CHRNB1 | CHRNA7 1/4885HTR3A 882/4885HTR3E 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.